title: Synthesis, biological evaluation, and molecular modeling of abiraterone analogues: novel CYP17 inhibitors for the treatment of prostate cancer.
abstract: Abiraterone, a steroidal cytochrome P450 17alpha-hydroxylase-17,20-lyase inhibitor (CYP17), is currently undergoing phase II clinical trials as a potential drug for the treatment of androgen-dependent prostate cancer. Since steroidal compounds often show side effects attributable to their structure, we have tried to replace the sterane scaffold by nonsteroidal core structures. The design and synthesis of 20 new abiraterone mimetics are described. Their activities have been tested with recombinant human CYP17 expressed in E. coli. Promising compounds were further evaluated for selectivity against CYP11B1, CYP11B2, and the hepatic CYP3A4. Compounds 19 and 20 showed comparable activity to abiraterone (IC50 values of 144 and 64 nM vs 72 nM) and similar or even better selectivity against the other CYP enzymes. Selected compounds were also docked into our homology model, and the same binding modes as for abiraterone were found.
authors.affiliation: Pharmaceutical and Medicinal Chemistry, Saarland University, P.O. Box 151150, D-66041 Saarbrücken, Germany.
authors.forename: Mariano A E
authors.initials: MA
authors.lastname: Pinto-Bazurco Mendieta
authors.forename: Matthias
authors.initials: M
authors.lastname: Negri
authors.forename: Carsten
authors.initials: C
authors.lastname: Jagusch
authors.forename: Ursula
authors.initials: U
authors.lastname: Müller-Vieira
authors.forename: Thomas
authors.initials: T
authors.lastname: Lauterbach
authors.forename: Rolf W
authors.initials: RW
authors.lastname: Hartmann
mesh_terms: D000736:Androstenes; D000737:Androstenols / Q000138:chemical synthesis* / Q000494:pharmacology* / Q000627:therapeutic use; D001713:Biphenyl Compounds / Q000138:chemical synthesis / Q000494:pharmacology / Q000627:therapeutic use; D004791:Enzyme Inhibitors / Q000138:chemical synthesis* / Q000494:pharmacology* / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008958:Models, Molecular; D011471:Prostatic Neoplasms / Q000188:drug therapy*; D011994:Recombinant Proteins / Q000187:drug effects; D013254:Steroid 17-alpha-Hydroxylase / Q000037:antagonists & inhibitors*
chemical_list: D000736:Androstenes; D000737:Androstenols; D001713:Biphenyl Compounds; D004791:Enzyme Inhibitors; D011994:Recombinant Proteins; D013254:Steroid 17-alpha-Hydroxylase; C089740:abiraterone